Implications of cognitive impairments on functional outcomes in major depressive disorder

Greer, Tracy L.; Hatt, Cassandra R.

doi:10.1017/cbo9781139860567.011

Cited by 1 publication

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cognitive difficulties in domains such as memory, attention and executive functioning can affect patient comprehension of treatment instructions, thereby contributing to poor treatment adherence in mood disorders. 44,45 Thus, the therapist should consider adapting the form of instructions to suit the patient: for example, supplementing verbal instruction with visuals, and frequent check-in to provide opportunities to ask questions and assess comprehension. Further, deficits in motivation and effort are integral to cognitive performance in mood disorders, 46 and warrant consideration for their influence on treatment adherence.…”

Section: Improving Adherencementioning

confidence: 99%

Clinical and methodological considerations for psychological treatment of cognitive impairment in major depressive disorder

et al. 2020

View full text Add to dashboard Cite

Background Cognitive impairment is considered a core feature of major depressive disorder (MDD) and research into psychological treatments aiming to address cognitive impairment are gaining momentum. Compared with the well-established research base of cognitive treatment trials in schizophrenia, including meta-analyses, mood disorder research is much more preliminary. Aims To focus on identifying the important factors to consider in developing larger-scale psychological treatment trials targeting cognitive impairment in mood disorders. Trial design recommendations have been published for cognitive treatment trials in bipolar disorder. Method An in-depth discussion of methodological considerations in the development of cognitive treatment trials for MDD. Results Methodological considerations include: screening for, and defining, cognitive impairment; mood state when cognitive intervention begins; medication monitoring during cognitive interventions; use of concomitant therapy; level of therapist involvement; duration and dose of treatment; choice of specific cognitive training exercises; home practice; improving adherence; appropriate comparison therapies in clinical trials; and choice of primary outcomes. Conclusions As well as guidance for clinical trial development, this review may be helpful for clinicians wanting to provide cognitive interventions for individuals with MDD.

show abstract

Section: Improving Adherencementioning

confidence: 99%